Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Cabot

Showing results (131-140 of 153) with videos related to

Pageof 16
Sort By:
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 5, 2008
A role for ceramide in driving cancer cell resistance to doxorubicinYong-Yu Liu, Jing Yuan Yu, Dongmei Yin, et al.
Molecular Cancer Therapeutics|September 16, 2008
N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killingHongtao Wang, Barry J Maurer, Yong-Yu Liu, et al.
Molecular Cancer Research : MCR|November 21, 2019
Ceramide Analogue SACLAC Modulates Sphingolipid Levels and <i>MCL-1</i> Splicing to Induce Apoptosis in Acute Myeloid LeukemiaJennifer M Pearson, Su-Fern Tan, Arati Sharma, et al.
Journal of Leukemia (Los Angeles, Calif.)|February 28, 2017
Engraftment of Human Primary Acute Myeloid Leukemia Defined by Integrated Genetic Profiling in NOD/SCID/IL2rγnull Mice for Preclinical Ceramide-Based Therapeutic EvaluationBrian M Barth, Nichole R Keasey, Xujung Wang, et al.
Biochimica Et Biophysica Acta. Bioenergetics|September 4, 2022
Intrinsic adaptations in OXPHOS power output and reduced tumorigenicity characterize doxorubicin resistant ovarian cancer cellsJames T Hagen, McLane M Montgomery, Ericka M Biagioni, et al.
Elife|June 16, 2021
Intrinsic OXPHOS limitations underlie cellular bioenergetics in leukemiaMargaret Am Nelson, Kelsey L McLaughlin, James T Hagen, et al.
Biorxiv : the Preprint Server for Biology|November 14, 2023
Acid Ceramidase Inhibitor LCL-805 Antagonizes Akt Signaling and Promotes Iron-Dependent Cell Death in Acute Myeloid LeukemiaJohnson Ung, Su-Fern Tan, Todd E Fox, et al.
Cancer Biology & Therapy|July 29, 2011
Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancerYixing Jiang, Nicole A DiVittore, James M Kaiser, et al.
Journal of Lipid Research|April 10, 2019
Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulationSu-Fern Tan, Wendy Dunton, Xin Liu, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|December 10, 2021
Alterations in sphingolipid composition and mitochondrial bioenergetics represent synergistic therapeutic vulnerabilities linked to multidrug resistance in leukemiaKelsey H Fisher-Wellman, James T Hagen, Miki Kassai, et al.
Pageof 16

Showing results (131-140 of 153) with videos related to

Sort By:
Pageof 16
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 5, 2008
A role for ceramide in driving cancer cell resistance to doxorubicinYong-Yu Liu, Jing Yuan Yu, Dongmei Yin, et al.
Molecular Cancer Therapeutics|September 16, 2008
N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killingHongtao Wang, Barry J Maurer, Yong-Yu Liu, et al.
Molecular Cancer Research : MCR|November 21, 2019
Ceramide Analogue SACLAC Modulates Sphingolipid Levels and <i>MCL-1</i> Splicing to Induce Apoptosis in Acute Myeloid LeukemiaJennifer M Pearson, Su-Fern Tan, Arati Sharma, et al.
Journal of Leukemia (Los Angeles, Calif.)|February 28, 2017
Engraftment of Human Primary Acute Myeloid Leukemia Defined by Integrated Genetic Profiling in NOD/SCID/IL2rγnull Mice for Preclinical Ceramide-Based Therapeutic EvaluationBrian M Barth, Nichole R Keasey, Xujung Wang, et al.
Biochimica Et Biophysica Acta. Bioenergetics|September 4, 2022
Intrinsic adaptations in OXPHOS power output and reduced tumorigenicity characterize doxorubicin resistant ovarian cancer cellsJames T Hagen, McLane M Montgomery, Ericka M Biagioni, et al.
Elife|June 16, 2021
Intrinsic OXPHOS limitations underlie cellular bioenergetics in leukemiaMargaret Am Nelson, Kelsey L McLaughlin, James T Hagen, et al.
Biorxiv : the Preprint Server for Biology|November 14, 2023
Acid Ceramidase Inhibitor LCL-805 Antagonizes Akt Signaling and Promotes Iron-Dependent Cell Death in Acute Myeloid LeukemiaJohnson Ung, Su-Fern Tan, Todd E Fox, et al.
Cancer Biology & Therapy|July 29, 2011
Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancerYixing Jiang, Nicole A DiVittore, James M Kaiser, et al.
Journal of Lipid Research|April 10, 2019
Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulationSu-Fern Tan, Wendy Dunton, Xin Liu, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|December 10, 2021
Alterations in sphingolipid composition and mitochondrial bioenergetics represent synergistic therapeutic vulnerabilities linked to multidrug resistance in leukemiaKelsey H Fisher-Wellman, James T Hagen, Miki Kassai, et al.
Pageof 16